The Fas/Fas ligand system and cancer: Immune privilege and apoptosis

Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology

Volumn 25, Issue 1, 2003, Pages 19-30

  Abrahams, Vikki M ^b   Kamsteeg, Marijke ^b   Mor, Gil ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Apoptosis; FasL; Ovarian cancer; Secreted FasL

Indexed keywords

CASPASE; FAS ANTIGEN; FAS LIGAND; SEX HORMONE;

APOPTOSIS; CANCER; CANCER IMMUNOLOGY; CANCER MODEL; CELL MEMBRANE; CELL PROTECTION; CELL SURFACE; FEMALE GENITAL SYSTEM; FEMALE GENITAL TRACT CANCER; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; LYMPHOCYTE; OVARY CANCER; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL;

ANTIGENS, CD95; APOPTOSIS; BLOTTING, WESTERN; CELL SURVIVAL; CULTURE TECHNIQUES; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC SURVEILLANCE; MEMBRANE GLYCOPROTEINS; MICROSCOPY, FLUORESCENCE; MODELS, BIOLOGICAL; NEOPLASMS; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR ESCAPE;

EID: 0041411313     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1385/MB:25:1:19     Document Type: Review

References (41)

1. Igney, F. H. and Krammer, P. H. (2002) Immune escape of tumors: apoptosis resistance and tumor counterattack. J. Leukoc. Biol. 71, 907-920.
2. O'Connell, J., O'Sullivan, G., Collins, J., and Shanahan, F. (1996) The Fas counter attack: Fas mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184, 1075-1082.
3. Griffith, T., Brunner, T., Fletcher, S., Gree, D., and Ferguson, T. (1995) Fas ligand induces apoptosis as a mechanism of immune privilege. Science 270, 1187-1192.
4. Gutierrez, L. S., Eliza, M., Niven-Fairchild, T., Naftolin, F., and Mor, G. (1999) The Fas/Fas-ligand system: a mechanism for immune evasion in human breast carcinomas. Breast Cancer Res. Treat. 54, 245-253.
5. Reimer, T., Herrnring, C., Koczan, D., et al. (2000) FasL:Fas ratio - a prognostic factor in breast carcinomas. Cancer Res. 60, 822-828.
6. Niehans, G., Brunner, T., Frizelle, S., et al. (1997) Human lung carcinomas express Fas ligand. Cancer Res. 57, 1007-1012.
7. Shiraki, K., Tsuji, N., Shioda, T., Isselbacher, K., and Takahashi, H. (1997) Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc. Natl. Acad. Sci. USA 94, 6420-6425.
8. Mor, G., Kohen, F., Garcia-Velasco, J., et al. (2000) Regulation of Fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen. J. Steroid Biochem. Mol. Biol. 73, 185-194.
9. Chappell, D. B. and Restifo, N. P. (1998) T cell-tumor cell: a fatal interaction? Cancer Immunol. Immunother. 47, 65-71.
10. Chappell, D. B., Zaks, T. Z., Rosenberg, S. A., and Restifo, N. P. (1999) Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res. 59, 59-62.
11. Nagata, S. (1994) Fas and Fas ligand: a death factor and its receptor. Adv. Immunol. 57, 129-135.
12. Mogil, R., Radvanyi, L., Gonzalez-Quintial, R., et al. (1995) Fas (CD95) participates in peripheral T cell deletion and associated apoptosis in vivo. Int. Immunol. 7, 1451-1458.
13. Brunner, T., Mogil, R., LaFace, D., et al. (1995) Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373, 441-444.
14. +)-independent T cell-mediated cytotoxicity. J. Exp. Med. 177, 195-200.
15. Song, J., Sapi, E., Brown, W., et al. (2000) Roles of Fas and Fas ligand during mammary gland remodeling. J. Clin. Invest. 106, 1209-1220.
16. Song, J., Rutherford, T., Brown, S., and Mor, G. (2002) Hormonal regulation of Fas and FasL expression and apoptosis in the normal human endometrium. Mol. Hum. Reprod. 8, 447-455.
17. Mor, G., Gutierrez, L., Eliza, M., Kahyaoglu, F., and Arici, A. (1998) Fas-Fas ligand system induced apoptosis in human placenta and gestational trophoblastic disease. Am. J. Reprod. Immunol. 40, 89-94.
18. Bechmann, I., Mor, G., Nilsen, J., Eliza, M., Nitsch, R., and Naftolin, F. (1999) FasL (CD95L, Ap01L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier. Glia 27, 62-74.
19. Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A., and Duke, R. (1995) A role for CD95 ligand in preventing graft rejection. Science 377, 630-632.
20. Nagata, S. (1997) Apoptosis by death factor. Cell 88, 355-365.
21. Wallach, D., Varfolomeev, E. E., Malinin, N. L., Goltsev, Y. V., Kovalenko, A. V., and Boldin, M. P. (1999) Tumor necrosis factor receptor and Fas signaling mechanisms. Annu. Rev. Immunol. 17, 331-367.
22. Schmitz, I., Kirchhoff, S., and Krammer, P. H. (2000) Regulation of death receptor-mediated apoptosis pathways. Int. J. Biochem. Cell. Biol. 32, 1123-1136.
23. Miyashita, T., Mami, U., Inoue, T., Reed, J. C., and Yamada, M. (1997) Bcl-2 relieves the trans-repressive function of the glucocorticoid receptor and inhibits the activation of CPP32-like cysteine proteases. Biochem. Biophys. Res. Commun. 233, 781-787.
24. Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., et al. (1996) FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85, 817-827.
25. Kim, Y., Suh, N., Spore, M., and Reed, J. C. (2002) An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J. Biol. Chem. 277, 22,320-22,329.
26. Krueger, A., Schmitz, I., Baumann, S., Krammer, P. H., and Kirchhoff, S. (2001) Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J. Biol. Chem. 276, 20,633-20,640.
27. Deveraux, Q. L., Roy, N., Stennicke, H. R., et al. (1998) IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 17, 2215-2223.
28. Kamsteeg, M., Rutherford, T., Sapi, E., et al. (2003) Phenoxodiol - an isoflavon analogue - induces apoptosis in chemo-resistant ovarian cancer cells. Oncogene, 22, 2611-2620.
29. Rabinowich, H., Reichert, T., Kashii, Y., Gastman, B., Bell, M., and Whiteside, T. (1998) Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells: implications for altered expression of T cell receptor in tumor-associated lymphocytes. J. Clin. Invest. 101, 2579-2588.
30. Allison, J., Georgiou, H. M., Strasser, A., and Vaux, D. L. (1997) Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege on islet allografts. Proc. Natl. Acad. Sci. USA 94, 3943-3947.
31. Chen, J., Sun, Y., and Nabel, G. (1998) Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 282, 1714-1717.
32. Kang, S. M., Hoffmann, A., Le, D., Springer, M. L., Stock, P. G., and Blau, H. M. (1997) Immune response and myoblasts that express Fas ligand. Science 278, 1322-1324.
33. Restifo, N. P. (2000) Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape. Nat. Med. 6, 493-495.
34. Andreola, G., Rivoltini, L., Castelli, C., et al. (2002) Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J. Exp. Med. 195, 1303-1316.
35. Abrahams, V., Straszewski, S., Kamsteeg, M., et al. (2003) Epithelial ovarian cancer secrete functional Fas ligand. Cancer Res., in press.
36. Kang, S. M., Braat, D., Schneider, D. B., et al. (2000) A noncleavable mutant of Fas ligand does not prevent neutrophilic destruction of islet transplants. Transplantation 69, 1813-1817.
37. Hohlbaum, A. M., Moe, S., and Marshak-Rothstein, A. (2000) Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J. Exp. Med. 191, 1209-1220.
38. Mor, G., Wei, Y., Santen, R., et al. (1998) Macrophages, estrogen and the microenvironment of breast cancer. J. Steroid Biochem. Mol. Biol. 67, 403-411.
39. Ben-Hur, H., Gurevich, P., Huszar, M., et al. (2000) Apoptosis and apoptosis-related proteins (Fas, Fas ligand, Blc-2, p53) in lymphoid elements of human ovarian tumors. Eur. J. Gynaecol. Oncol. 21, 53-57.
40. Song, J., Sapi, E., Brown, W., et al. (2000) Expression of Fas and Fas ligand during pregnancy, lactation and involution and its potential role during mammary gland remodeling. J. Clin. Invest. 106, 1209-1224.
41. Mor, G., Straszewski, S., and Kamsteeg, M. (2002) Role of the Fas/Fas ligand system in female reproductive organs: survival and apoptosis. Biochem. Pharmacol. 64, 1305.